LION bioscience and TEMIS Announce Partnership to Enhance Text Mining Solutions for the Life Science Industry (August 2004)
LION bioscience and TEMIS Announce Partnership to Enhance Text Mining Solutions for the Life Science Industry.

Cambridge, MA, USA, Heidelberg, Germany, Paris, France, August 3, 2004 LION bioscience (Nasdaq: LEON) and TEMIS today announced that they have entered into a collaboration in the area of Text Mining. Under this agreement, TEMIS will provide their Text Mining Technology to LION for integration into SRS and LION Target Engine. As part of the agreement, LION becomes a preferred reseller for TEMIS software in the life sciences and will also develop and market custom thesauri and language rules for data extraction using the TEMIS technology (Skill Cartridges).

LION is integrating the TEMIS Insight Discoverer Extractor and Skill Cartridges for biological and clinical text data into SRS and LION Target Engine. Using state-of-the-art natural language processing (NLP) Text Mining technology provided by TEMIS, structured content can be extracted from any text document, such as publicly available scientific literature or those contained in proprietary collections of reports. By integrating this technology, users are given access to a virtually infinite amount of information, which can then be further analyzed using the LION applications.

Life Sciences companies have been struggling to harvest structured data from text documents in order to improve the decision making process in drug discovery. TEMIS, a leading provider of Text Mining solutions in the Life Sciences, ideally suits this need, said Dr. Daniel Keesman, co-CEO and COO of LION bioscience.

"The integration of the heterogenous information in the Life Science industry is a formidable challenge and will eventually lead to an increase of efficiency of the drug discover process. With LION bioscience, the leading provider of integration technologies in Life Sciences, we have found the ideal partner," said Charles Huot, CEO of TEMIS.

For further information please contact:
LION bioscience:
Julia Fritz
Public Relations Officer
+49 (0) 6221-4038 158
julia.fritz@lionbioscience.com
TEMIS:
Dr. Gunther Kurapkat
Director Business Development
+49 (0) 6221-1375 313
Gunther.kurapkat@temis-group.com
Martine Falhon
Corporate Communications
+33 (0)4 76 61 51 79
martine.falhon@temis-group.com

About TEMIS
TEMIS, a leader in Text Mining, develops and markets software solutions for Text Mining, enabling the optimization of information processing by transforming free text into data that can be analyzed for information extraction or automatic classification of documents. TEMIS (http://www.temis-group.com) products play a critical role in fields where information processing is complex due to the volume of information, as well as provide substantial productivity gains. The excellent quality of TEMIS results is due to the use of adaptive and domain-specific Skill Cartridgesä containing a set of compiled rules (e.g. Biological Entities Skill Cartridgeä co-developed with Fraunhofer Institute SCAI). The company was created in September 2000 and currently has subsidiaries in France, Germany, Italy, UK and partners in the rest of Europe and the United States. Customers include Alcatel, Bertelsmann, Dresdner Bank, EADS CCR, France Télécom, IBM, IPSEN, Novartis, Renault, TIM-Telecom Italia Mobile and Total.

About LION bioscience
LION bioscience (ISIN: DE0005043509, Reuters: LIOG, Bloomberg: LIO, Nasdaq: LEON) provides proven information and knowledge management solutions to significantly improve life science R&D performance and productivity. Since it was founded in 1997, the company has become a recognized leader in the area of life sciences informatics. LION has operations worldwide in Heidelberg, Germany, Cambridge, UK, Cambridge, MA, USA. LION?s products are distributed by CTC Systems in Japan and DigiGenomics in Taiwan.
LION?s (http://www.lionbioscience.com) solutions are used by more than 27,000 researchers at 300 academic and industrial customers globally. LION?s offerings include SRS for bioinformatics data access, LION Target Engine for target identification and validation, LION Lead Engine for lead identification and optimization, iDEA pkEXPRESS? with analysis and prediction tools for ADME, and LION SolutionCenter professional services.


Except for the historical information contained herein, the matters set forth in this press release are forward looking within the meaning of the Private Securities Litigation Reform Act of 1995, and other applicable U.S. and German laws. These forward-looking statements may include projections, assumptions, estimates, targets, and descriptions of future events. Such statements are based on currently available information and on LION's current expectations as to future events that may not prove to be accurate. These statements are not guarantees of future performance and involve risks and uncertainties that are difficult to predict. Many factors could cause the actual results, performance or achievements of LION to be materially different from those that may be projected, expected, targeted, expressed or implied by such statements. All roll-out plans and future dates with respect to completion of development and market release of LION products are target dates only based on the company's current planning and may change in the future. Any delays in the current product release schedule will have a materially adverse effect on the company?s targets for fiscal year. We refer you to LIONs Annual Reports on Form 20-F, as recently filed with the Securities and Exchange Commission (SEC) on April 20, 2004 (Form 20-F/A), in which these and other risk factors are discussed. In the event of any material conflicts between the two documents, Form 20-F - resp. Form 20-F/A - should be relied on. LION expressly disclaims any obligation or undertaking to release publicly any updates, revisions or corrections to any forward-looking statements or historical information contained in this announcement, whether as a result of new information, change of assumptions or business model, future developments or otherwise